AIM ImmunoTech Inc. has entered into agreements to convert a portion of its outstanding debt into equity. According to a filing with the U.S. Securities and Exchange Commission dated September 3, 2026, the company executed two exchange agreements with Streeterville Capital, LLC.
The agreements relate to a Promissory Note dated November 18, 2025. Under the terms of the transaction, AIM ImmunoTech converted approximately $450,000 of the principal balance of that note into 1,921,441 shares of common stock. The conversion was executed at an average price of approximately $0.234 per share.
The company notes that the issuance of these shares was exempt from the registration requirements of the Securities Act of 1933. The exemption was granted under Section 3(a)(9) of the Act, which allows for the exchange of securities between a company and an existing security holder without the payment of commissions or other remuneration.
The filing indicates that the stockholders of AIM ImmunoTech previously approved the conversion or satisfaction of the Promissory Note. This approval was granted at a special meeting of stockholders held on July 15, 2026, in accordance with NYSE American Company Guide Sections 713(a) and 713(b).
